Taro Pharmaceutical Industries (NYSE: TARO)The shares of the shares were reassessed by the HC Wainwright stock researchers in a report that was issued on Friday 10 August, according to The Fly. They currently have a target price of $ 120.00 on the shares. The price target of HC Wainwright would indicate a potential advantage of 13.59% compared to the company's previous closure.
TARO has been the subject of several other reports. Zacks Investment Research has increased Taro Pharmaceutical Industries from a & # 39; hold & # 39; credit to a & # 39; buy & # 39; rating and a target price of $ 129.00 for the company in a research report on Saturday, May 26. TheStreet renewed Taro Pharmaceutical Industries from a "c +" rating to a "b" rating in a research report on Monday 4 June. One equity research analyst assessed the shares with a sell rating, two gave a hold rating and one gave a buy rating to the company. The company has an average rating of & # 39; Hold & # 39; and an average price target of $ 124.50.
TARO shares traded $ 1.26 during mid-day trading and reached $ 105.64. The company had a trading volume of 34,455 shares, compared with the average volume of 40,556. Taro Pharmaceutical Industries has a twelve month low of $ 93.01 and a 12 month high of $ 128.46. The stock has a market capitalization of $ 4.19 billion, a PE ratio of 17.09 and a beta of 0.50.
Taro Pharmaceutical Industries (NYSE: TARO) last released its quarterly results on Thursday 9 August. The company reported earnings per share of $ 1.71 this quarter, with the Zacks consensus estimate of $ 2.33 being missed with ($ 0.62). The company had sales of $ 154.62 million for the quarter compared with analyst estimates of $ 179.54 million. Taro Pharmaceutical Industries had a net margin of 34.18% and a return on equity of 11.73%. analysts expect that Taro Pharmaceutical Industries will post earnings per share of 7.65 per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its shareholdings in Taro Pharmaceutical Industries by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 20,109 shares of the company's shares worth $ 2,326,000 after acquiring an additional 8,492 shares in the last quarter. Nomura Holdings Inc. bought a new position in Taro Pharmaceutical Industries in the second quarter of approximately $ 393,000. California Public Employees Retirement System increased its shareholdings in Taro Pharmaceutical Industries by 7.6% in the second quarter. The California Public Employees Retirement System now owns 36,869 shares of the company's shares worth $ 4,265,000 after purchasing 2,611 additional shares in the last quarter. Paloma Partners Management Co acquired a new position in Taro Pharmaceutical Industries in the second quarter of approximately $ 492,000. Finally, Dynamic Technology Lab Private Ltd canceled its shareholdings in Taro Pharmaceutical Industries in the second quarter by 31.1%. Dynamic Technology Lab Private Ltd now owns 3,230 shares of the company's shares worth $ 374,000 after acquiring another 766 shares in the last quarter. Hedge funds and other institutional investors hold 10.41% of the company's shares.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, is engaged in the development, production and marketing of pharmaceutical products in the United States, Canada, Israel and internationally. It offers non-prescription and readily available pharmaceutical products that target primary areas, including topical creams and ointments, liquids, capsules and tablets in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.
Featured article: earnings per share
Receive news and ratings for Taro Pharmaceutical Industries Daily – Enter your email address below to receive a concise, daily summary of the latest news and ratings from analysts for Taro Pharmaceutical Industries and related companies with the FREE daily email newsletter from MarketBeat.com.